| Trial ID: | L5798 |
| Source ID: | NCT00543959
|
| Associated Drug: |
Mk0533
|
| Title: |
Efficacy and Tolerability of MK0533 in Patients With Type 2 Diabetes (0533-005)
|
| Acronym: |
|
| Status: |
TERMINATED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Diabetes Mellitus Type 2
|
| Interventions: |
DRUG: MK0533|DRUG: Comparator: Placebo (unspecified)|DRUG: Comparator: pioglitazone
|
| Outcome Measures: |
Primary: Body fluid gain from baseline after 12 weeks, 12 weeks | Secondary: Fasting plasma glucose after 12 weeks, 12 weeks
|
| Sponsor/Collaborators: |
Sponsor: Merck Sharp & Dohme LLC
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
PHASE2
|
| Enrollment: |
346
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: DOUBLE (PARTICIPANT, INVESTIGATOR)|Primary Purpose: TREATMENT
|
| Start Date: |
2006-06
|
| Completion Date: |
2007-08
|
| Results First Posted: |
|
| Last Update Posted: |
2015-06-23
|
| Locations: |
|
| URL: |
https://clinicaltrials.gov/show/NCT00543959
|
